Announcements Trials

Browse Landscape

Phase

Status

Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 40 Carcinoma, Non-Small-Cell Lung 40 Carcinoma, Renal Cell 30 Urinary Bladder Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 15 Lung Neoplasms 15 Colorectal Neoplasms 15 Stomach Neoplasms 13 Pancreatic Neoplasms 13 Neoplasms 13 Neoplasm Metastasis 13 Ovarian Neoplasms 11 Sarcoma 10 Hodgkin Disease 10 Glioblastoma 10 Carcinoma, Transitional Cell 10 Rectal Neoplasms 9 Triple Negative Breast Neoplasms 8 Prostatic Neoplasms 8 Kidney Neoplasms 8 Carcinoma, Hepatocellular 8 Small Cell Lung Carcinoma 7 Esophageal Neoplasms 7 Colonic Neoplasms 7 Breast Neoplasms 7 Head and Neck Neoplasms 6 Skin Neoplasms 5 Lymphoma, Large B-Cell, Diffuse 5 Carcinoma, Neuroendocrine 5 Carcinoma, Merkel Cell 5

Interventions

pembrolizumab 2 Robotic Surgical Procedures 2 avelumab 1 Sunitinib 1 Nivolumab 1 Magnetic Resonance Spectroscopy 1 Doxorubicin 1 Cyclophosphamide 1 Cisplatin 1 Cetuximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Thymoma × Nivolumab × Clear all

NCT03134118 2026-05-15

NIVOTHYM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Active not recruiting

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡